Physician profile
David Colbert
NPI 1790848729
$19,357.83
in general payments reported to CMS, 2019-2025
19 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $72.43 · 2021: $425 · 2022: $140 · 2023: $261 · 2024: $18K · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,500.00 |
| Food and Beverage | $606.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $18,120.54 | 2019-2024 | Xeomin |
| Allergan, INC. | $427.07 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $193.98 | 2019-2024 | |
| Abbvie INC. | $167.40 | 2024-2025 | |
| Janssen Biotech, INC. | $73.23 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $57.77 | 2024-2025 | |
| Amgen INC. | $54.84 | 2023-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $46.24 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $29.01 | 2023 | Adbry |
| Strata Skin Sciences, INC. | $28.94 | 2019-2022 | |
| Lilly USA, LLC | $20.66 | 2020 | |
| Biofrontera INC. | $20.16 | 2022 | |
| Genentech USA, INC. | $19.98 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $19.17 | 2020 | |
| Galderma Laboratories, L.P. | $19.02 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $17.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2021 | |
| Journey Medical Corporation | $15.46 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Colbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.